Expat’s remote surgery medtech scores $92 million Series B for stroke care

详细摘要
The funds are for a University of California clinical trial by a surgical robot designed to let specialists treat stroke patients remotely
US venture firm DCVC led the round, with existing backers Blackbird, Tony Fadell’s Build Collective, Divergent Capital and KdT Ventures chipping in alongside the the University of California’s investment office, Skip Capital and super fund Hostplus as new investors.
Remedy previously raised US$35 million across its Seed and Series A rounds.
The fresh capital is for a clinical trial across the University of California’s network by a surgical robot designed to let specialists treat stroke patients hundreds of kilometres away. The medtech is seeking US Food and Drug Administration approval for procedures on the blood vessels supplying the brain. It also plans to place prototype robots with clinical partners, including the Australian Stroke Alliance.
Bell spent eight years in medicine, including cardiac surgery and air retrieval, before studying at Stanford, where he met his cofounder and CTO Jake Sganga. In 2021, the pair lined a garage in Venice Beach with lead, bought a second-hand X-ray machine and had a colleague in Berkeley operate their prototype remotely.
“This funding will allow our world-leading hardware, software, and machine learning teams to progress the N1 system towards clinical trials and potential FDA approval, while also developing additional features including full autonomy,” Sganga said.
By continuing, you agree to our Terms & Conditions and Privacy Policy.
The N1 robot lets a specialist at a console steer a catheter through a patient’s blood vessels. Its software uses machine learning to analyse scans, simulate procedures and match a 3D map of the vessels to live X-ray images. The team is also developing autonomous functions.
In August 2025, a Toronto neurosurgeon used the N1 to perform diagnostic angiograms on two patients at a hospital 6km away. A clinical team stayed with each patient while Pereira guided the catheter to check for narrowed or blocked vessels.
The N1 has yet to secure approval for routine clinical use anywhere.
文章开头,摘自Startup Daily。如需阅读全文,请前往媒体网站。
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.startupdaily.net)




